Clareo Health | A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
History of chronic migraine with or without aura consistent with a diagnosis according to the International Classification of Headache Disorders, 3rd Edition (ICHD-3) (2018) for at least 6 months as of Visit 1.
During the last 28 days of the screening/baseline period, and as per eDiary:
* Participant must have completed the eDiary for a minimum of 20 out of 28 days.
* Participant has \>= 15 headache days.
* Participant has \>= 8 migraine days.
You may not be if
Clinically significant hypertension per investigator's judgment.
History of any clinically significant hematologic, endocrine, pulmonary, renal, hepatic, gastrointestinal, cardiovascular or neurologic disease.
